John Bigelow, Sep 30, 2013
Thirteen years ago-in 2000-the Federal Trade Commission (“FTC”) and private plaintiffs began fighting certain kinds of settlements that sometimes arise in litigation over patents for pharmaceutical products. Initially dubbed “Reverse Payment” settlements and later “Pay for Delay” settlements by their critics, the challenged settlements come about when the manufacturer of a branded and patented drug settles patent infringement litigat
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 35.171.45.182
Please verify email or join us to access premium content!